Pneumococcal infection

disease
On this page

Also known as infection, pneumococcalinfection, Streptococcus pneumoniaeinfections, pneumococcalinfections, Streptococcus pneumoniaepneumoniae infection, Streptococcuspneumoniae infections, StreptococcusStreptococcus pneumoniae caused disease or disorderStreptococcus pneumoniae disease or disorderStreptococcus pneumoniae infectionStreptococcus pneumoniae infectionsStreptococcus pneumoniae infectious disease

Summary

Pneumococcal infection (MONDO:0005114) is a disease and 176 clinical trials. Top therapeutic interventions include streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197, colistimethate sodium, and elasomeran. A subtype of streptococcal infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 176

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepneumococcal infection
Mondo IDMONDO:0005114
EFOEFO:0000772
MeSHD011008
SNOMED CT16814004
UMLSC0032269
MedGen18528
Is cancer (heuristic)no

Also known as: infection, pneumococcal · infection, Streptococcus pneumoniae · infections, pneumococcal · infections, Streptococcus pneumoniae · pneumococcal infection · pneumoniae infection, Streptococcus · pneumoniae infections, Streptococcus · Streptococcus pneumoniae caused disease or disorder · Streptococcus pneumoniae disease or disorder · Streptococcus pneumoniae infection · Streptococcus pneumoniae infections · Streptococcus pneumoniae infectious disease

Disease family

This is a subtype of streptococcal infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseasebacterial infectious diseasegram-positive bacterial infectionsstreptococcal infectionpneumococcal infection

Related subtypes (7): erysipelas, streptococcal meningitis, impetigo, scarlet fever, streptococcal toxic-shock syndrome, streptococcal sore throat, group B streptococcal infection

Subtypes (3): streptococcal pneumonia, pneumococcal meningitis, streptococcus pneumoniae discitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197Approved (phase 4)
Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae ToxoidApproved (phase 4)
Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein DApproved (phase 4)
Streptococcus Pneumoniae Polysaccharide Conjugated To Tetanus ToxoidApproved (phase 4)
ElasomeranPhase 3 (in late-stage trials)
Influenza Virus VaccinePhase 3 (in late-stage trials)
Penicillin GPhase 3 (in late-stage trials)
Sodium ChloridePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Rituximab.

Clinical trials & evidence

Clinical trials

Clinical trials: 176.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE354
Not specified41
PHASE427
PHASE126
PHASE218
PHASE1/PHASE27
EARLY_PHASE12
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04875819PHASE4RECRUITINGSafety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
NCT04945681PHASE4ACTIVE_NOT_RECRUITINGEvaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People
NCT06817421PHASE4NOT_YET_RECRUITINGOpportunistic Pneumococcal Immunisation Trial in MALnutrition
NCT06822907PHASE4RECRUITINGImmunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
NCT00197808PHASE4COMPLETEDResponse of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines
NCT00276107PHASE4COMPLETEDStudy Evaluating Prevenar Vaccine in Healthy Infants
NCT00304382PHASE4COMPLETEDHumoral Determinants of Immunity to Pneumococcal Infection
NCT00368186PHASE4TERMINATEDImmunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.
NCT00625677PHASE4COMPLETEDStudy to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life
NCT00744263PHASE4COMPLETEDStudy Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT01193582PHASE4COMPLETEDA Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
NCT01577771PHASE4COMPLETEDImmunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso
NCT02062281PHASE4COMPLETEDStudy of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
NCT02225327PHASE4COMPLETEDMF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
NCT02260882PHASE4COMPLETEDRevaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
NCT02582047PHASE4COMPLETEDInfluenza Vaccine and Pneumococcal Vaccine
NCT02637583PHASE4COMPLETEDSequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels
NCT02787863PHASE4COMPLETEDClinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
NCT03095326PHASE4COMPLETEDPneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia
NCT03489018PHASE4COMPLETEDThe Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
NCT03552445PHASE4COMPLETEDImmunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine
NCT03619252PHASE4COMPLETEDPneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT04875858PHASE4UNKNOWNImmunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients
NCT04989465PHASE4COMPLETEDA Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05477693PHASE4COMPLETEDImmunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05731115PHASE4COMPLETEDLot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05767606PHASE4UNKNOWNConcomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years
NCT05759520PHASE3ACTIVE_NOT_RECRUITINGPhase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
NCT06608199PHASE3RECRUITINGA Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai’s PCV13-DT/TT Vaccine As Compared to Pfizer’s PCV13 Vaccine
NCT06838000PHASE3ACTIVE_NOT_RECRUITINGStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT07017777PHASE3RECRUITINGA Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
NCT00127153PHASE3COMPLETEDA Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)
NCT00189020PHASE3COMPLETEDEffect of Two Versus Three Pneumococcal Conjugate Vaccinations
NCT00310349PHASE3UNKNOWNPneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
NCT00378417PHASE3COMPLETEDEfficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes
NCT00427895PHASE3COMPLETEDStudy Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00452452PHASE3COMPLETEDStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children
NCT00452790PHASE3COMPLETEDStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
NCT00492557PHASE3COMPLETEDStudy Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
NCT00496093PHASE3COMPLETEDSafety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM19748
COLISTIMETHATE SODIUM41
ELASOMERAN41
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN41
ZINC ION31
CHEMBL120127901
CHEMBL407192701
CHEMBL475486201